医学
三阴性乳腺癌
肿瘤科
内科学
子群分析
乳腺癌
转移性乳腺癌
癌症
荟萃分析
作者
Binghe Xu,F. Ma,S. Wang,Z. Tong,W. Li,X. Wu,X. Wang,T. Sun,Y. Pan,H. Yao,X. Wang,T. Luo,J. Yang,X. Zeng,W. Zhao,X.J. Cong,Ning Wang,C. Xu,J.J. Chen
标识
DOI:10.1016/j.annonc.2022.10.031
摘要
About 30-40% of mTNBC patients (pts) have tumors with HER2 low expression, which might be a potential target of some novel anti-HER2 agents. Sacituzumab govitecan (SG), a novel Trop2-targeted antibody-drug conjugate, has been approved for second line onwards mTNBC treatment by Singapore and NMPA recently. To better understand the role of SG in the treatment of Chinese mTNBC with different HER2 expression level, subgroup data of EVER-132-001 were analyzed.
科研通智能强力驱动
Strongly Powered by AbleSci AI